cache

Home cache
  • Next Post
  • Previous Post

cache

David Dornan, PhD

/ Uncategorized

Share the Post

About the Author

Related Posts

Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa
nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I)
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit
Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors
Aadi Bioscience Appoints Brendan Delaney as Chief Operating Officer

Comments

Comments are closed.

  • Next Post
  • Previous Post